Metabolomics study during ECT for depression
Part of Mental health clinical trials.
This study measures changes in your blood and/or body chemistry while you receive electroconvulsive therapy (ECT) for a severe mood episode. The goal is to understand biological signals related to ECT and treatment-resistant depression, which may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You currently have a major depressive episode (a severe depression lasting enough to meet DSM-5 criteria).
- You have a diagnosis of major depression or bipolar disorder.
- Your depression severity score (MADRS) is above 22.
- Your depression is current and your care team has decided ECT is an appropriate treatment.
- You have tried two antidepressants at effective doses for at least 6 weeks each, and they did not work well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how ECT affects brain activity and inflammation in older adults with depression. It may help researchers understand why ECT works and improve treatment.
This study looks at brain wave patterns and markers of inflammation in people with depression that hasn't improved with other treatments and who are receiving electroconvulsive therapy (ECT, also known as shock therapy). The goal is to understand how these markers might relate to how well ECT works.
This study tests a way of adjusting (titrating) ECT treatment to improve outcomes in people with major depression or bipolar II. It’s mainly for those who already need ECT with right-side electrode placement.
This study tests whether adding a low dose of esketamine (a type of anesthesia) to modified electroconvulsive therapy (ECT) helps treat severe depression in teenagers. It aims to see if this combination works better and is safer than ECT alone.
This trial tests a new type of electric brain stimulation, called FEAST, as a treatment for severe depression. It aims to see if it can help improve mood with potentially fewer side effects than standard electroconvulsive therapy (ECT).
This study looks at blood markers (substances in blood) measured during electroconvulsive therapy, to understand how the treatment is working in the body. If you’re already being considered for ECT, you may be asked for blood samples as part of this research.
Hear when a new Major Depressive Episode trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.